Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

Abstract

The prevailing view of cold tumors as a singular immune-insensitive state is not merely imprecise, which is clinically misleading. Currently, we contend that cold tumors comprise a heterogeneous spectrum of resistance ecosystems by distinct, coexisting, dominant barriers. We argue that a universal “heating” strategy is unlikely to succeed; instead, durable clinical benefit will depend on barrier-directed immune reprogramming. We dissect this heterogeneity by linking a set of core mechanistic drivers to canonical hot, immune-desert, and immune-excluded phenotypes. The drivers include defective antigen processing and presentation, impaired T-cell priming, physical exclusion by aberrant vasculature, stromal components, metabolic exhaustion, and adaptive resistance. Our evaluation of emerging conversion strategies focuses not on their novelty but on capacity to neutralize a specific rate-limiting barrier. We also examine why combination and sequencing are indispensable, highlight translational gaps between preclinical models and human disease and propose a dynamic biomarker framework that extends beyond static PD-L1 assessment to capture real-time shifts in dominant barrier. Our central conclusion is that durable cold-to-hot conversion will require iterative, biomarker-guided and barrier-adaptive interventions that evolve alongside tumor counter-adaptation. The reframing positions immunotherapy resistance not as a terminal obstacle but as a manageable, dynamic challenge, offering a practical strategy for clinical translation.

Keywords

cold-to-hot tumor conversion / immune evasion / immunotherapy resistance / immunotherapy resistance plasticity / tumor microenvironment

References

[1] T. F. Greten, R. Schwabe, N. Bardeesy, et al., “Immunology and Immunotherapy of Cholangiocarcinoma,” Nature Reviews Gastroenterology & Hepatology 20, no. 6 (2023): 349–365.

[2] M. Zhang, C. Liu, J. Tu, et al., “Advances in Cancer Immunotherapy: Historical Perspectives, Current Developments, and Future Directions,” Molecular Cancer 24, no. 1 (2025): 136.

[3] A. D. Waldman, J. M. Fritz, and M. J. Lenardo, “A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice,” Nature Reviews Immunology 20, no. 11 (2020): 651–668.

[4] S. Zhao, H. Zhao, W. Yang, and L. Zhang, “The Next Generation of Immunotherapies for Lung Cancers,” Nature Reviews Clinical Oncology 22, no. 8 (2025): 592–616.

[5] Y. Chen, D. Wang, Y. Li, et al., “Spatiotemporal Single-Cell Analysis Decodes Cellular Dynamics Underlying Different Responses to Immunotherapy in Colorectal Cancer,” Cancer Cell 42, no. 7 (2024): 1268–1285.e1267.

[6] M. Pagadala, T. J. Sears, V. H. Wu, et al., “Germline Modifiers of the Tumor Immune Microenvironment Implicate Drivers of Cancer Risk and Immunotherapy Response,” Nature Communications 14, no. 1 (2023): 2744.

[7] B. Wu, B. Zhang, B. Li, et al., “Cold and Hot Tumors: From Molecular Mechanisms to Targeted Therapy,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 274.

[8] Y. T. Liu, Y. L. Wang, S. Wang, et al., “Turning Cold Tumors Into Hot Tumors to Ignite Immunotherapy,” Molecular Cancer 24, no. 1 (2025): 254.

[9] B. Ran, L. Xiao, Y. Liu, et al., “Dynamic Remodeling of Amino Acid Metabolism in Tumor-Associated Macrophages: Fueling Immunosuppression, Reshaping Tumor Niches, and Unlocking Metabolic Checkpoints,” Journal of Advanced Research 84 (2025): 775–803.

[10] X. Zhang, Y. Gao, W. Hu, et al., “Reactivating Exhausted Tumor-Infiltrating T Cells by a Bispecific DC-T Cell Engager in Mice,” Nature Communications 17, no. 1 (2026): 4081.

[11] E. J. Sayour, D. Boczkowski, D. A. Mitchell, and S. K. Nair, “Cancer mRNA Vaccines: Clinical Advances and Future Opportunities,” Nature Reviews Clinical Oncology 21, no. 7 (2024): 489–500.

[12] S. Sun, L. Liu, J. Zhang, et al., “The Role of Neoantigens and Tumor Mutational Burden in Cancer Immunotherapy: Advances, Mechanisms, and Perspectives,” Journal of Hematology & Oncology 18, no. 1 (2025): 84.

[13] J. Budczies, D. Kazdal, M. Menzel, et al., “Tumour Mutational Burden: Clinical Utility, Challenges and Emerging Improvements,” Nature Reviews Clinical Oncology 21, no. 10 (2024): 725–742.

[14] P. Grell, S. Borilova, P. Fabian, et al., “FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients With Advanced Melanoma and Non-Small Cell Lung Cancer,” Cancers (Basel) 15, no. 6 (2023): 1901.

[15] X. Zhang, M. Lao, K. Sun, et al., “Sphingolipid Synthesis in Tumor-Associated Macrophages Confers Immunotherapy Resistance in Hepatocellular Carcinoma,” Science Advances 11, no. 21 (2025): eadv0558.

[16] C. Montironi, F. Castet, P. K. Haber, et al., “Inflamed and Non-Inflamed Classes of HCC: A Revised Immunogenomic Classification,” Gut 72, no. 1 (2023): 129–140.

[17] M. M. LaRue, S. Parker, J. Puccini, et al., “Metabolic Reprogramming of Tumor-Associated Macrophages by Collagen Turnover Promotes Fibrosis in Pancreatic Cancer,” PNAS 119, no. 16 (2022): e2119168119.

[18] X. Kang, Y. Zhang, J. Song, et al., “A Photo-Triggered Self-Accelerated Nanoplatform for Multifunctional Image-Guided Combination Cancer Immunotherapy,” Nature Communications 14, no. 1 (2023): 5216.

[19] S. Li, Y. Yue, J. Du, et al., “Carrier-Free Nanoreshapers Disrupt Cancer-Associated Fibroblast Barriers and Alleviate Immunosuppression for Synergistically Potentiated Immunotherapy,” Journal of Controlled Release 393 (2026): 114835.

[20] H. Zhang, S. Li, S. Liu, et al., “Therapeutic Targeting of Cell Death-Immune Crosstalk in Cancer to Rewire the Tumor Immune Microenvironment,” Molecular Cancer 24, no. 1 (2025): 277.

[21] M. Tufail, C. H. Jiang, and N. Li, “Immune Evasion in Cancer: Mechanisms and Cutting-Edge Therapeutic Approaches,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 227.

[22] Y. Han, Y. Ma, M. Pei, et al., “Intratumoural Vaccination via Checkpoint Degradation-Coupled Antigen Presentation,” Nature 650, no. 8102 (2026): 736–747.

[23] T. Yang, S. Zhang, H. Yuan, et al., “Platinum-Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment,” Angewandte Chemie 62, no. 2 (2023): e202213337.

[24] S. Rottenberg, C. Disler, and P. Perego, “The Rediscovery of Platinum-Based Cancer Therapy,” Nature Reviews Cancer 21, no. 1 (2021): 37–50.

[25] K. L. Simpson, D. G. Rothwell, F. Blackhall, and C. Dive, “Challenges of Small Cell Lung Cancer Heterogeneity and Phenotypic Plasticity,” Nature Reviews Cancer 25, no. 6 (2025): 447–462.

[26] M. Roerden and S. Spranger, “Cancer Immune Evasion, Immunoediting and Intratumour Heterogeneity,” Nature Reviews Immunology 25, no. 5 (2025): 353–369.

[27] S. Dutta, A. Ganguly, K. Chatterjee, et al., “Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors,” Biology (Basel) 12, no. 2 (2023): 218.

[28] S. K. R. Noonepalle, L. Karabon, K. B. Chiappinelli, and A. Villagra, “Editorial: Genetic and Epigenetic Control of Immune Responses,” Frontiers in Immunology 12 (2021): 775101.

[29] Y. Yang and W. Wang, “Recent Progress in Immune Evasion Mechanisms of Triple-Negative Breast Cancer,” Journal of Translational Medicine 23, no. 1 (2025): 1314.

[30] N. B. Collins, R. Al Abosy, and B. C. Miller, “PI3K Activation Allows Immune Evasion by Promoting an Inhibitory Myeloid Tumor Microenvironment,” Journal for ImmunoTherapy of Cancer 10, no. 3 (2022): e003402.

[31] N. Nishida, “Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma,” Cancers (Basel) 13, no. 15 (2021): 3666.

[32] H. Hu, R. Cheng, Y. Wang, et al., “Oncogenic KRAS Signaling Drives Evasion of Innate Immune Surveillance in Lung Adenocarcinoma by Activating CD47,” Journal of Clinical Investigation 133, no. 2 (2023): e153470.

[33] G. Efe, A. K. Rustgi, and C. Prives, “p53 at the Crossroads of Tumor Immunity,” Nature Cancer 5, no. 7 (2024): 983–995.

[34] Y. Liu, B. R. Stockwell, X. Jiang, and W. Gu, “p53-Regulated Non-Apoptotic Cell Death Pathways and Their Relevance in Cancer and Other Diseases,” Nature Reviews Molecular Cell Biology 26, no. 8 (2025): 600–614.

[35] H. H. Wu, S. Leng, and D. D. Eisenstat, “Targeting p53 for Immune Modulation: Exploring Its Functions in Tumor Immunity and Inflammation,” Cancer Letters 617 (2025): 217614.

[36] L. Yehia, J. Ngeow, and C. Eng, “PTEN-Opathies: From Biological Insights to Evidence-Based Precision Medicine,” Journal of Clinical Investigation 129, no. 2 (2019): 452–464.

[37] K. Dhatchinamoorthy, J. D. Colbert, and K. L. Rock, “Cancer Immune Evasion through Loss of MHC Class I Antigen Presentation,” Frontiers in Immunology 12 (2021): 636568.

[38] H. Jung, H. S. Kim, J. Y. Kim, et al., “DNA Methylation Loss Promotes Immune Evasion of Tumours With High Mutation and Copy Number Load,” Nature Communications 10, no. 1 (2019): 4278.

[39] N. Duan, X. Hu, H. Qiu, et al., “Targeting the E2F1/Rb/HDAC1 Axis With the Small Molecule HR488B Effectively Inhibits Colorectal Cancer Growth,” Cell Death & Disease 14, no. 12 (2023): 801.

[40] D. Zingg, N. Arenas-Ramirez, D. Sahin, et al., “The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy,” Cell Reports 20, no. 4 (2017): 854–867.

[41] L. H. Chi, R. S. N. Cross, and R. P. Redvers, “MicroRNA-21 Is Immunosuppressive and Pro-Metastatic via Separate Mechanisms,” Oncogenesis 11, no. 1 (2022): 38.

[42] J. Wang, X. Zhao, Y. Wang, et al., “circRNA-002178 Act as a ceRNA to Promote PDL1/PD1 Expression in Lung Adenocarcinoma,” Cell Death & Disease 11, no. 1 (2020): 32.

[43] F. Ma, Y. Y. Lei, M. G. Ding, et al., “LncRNA NEAT1 Interacted With DNMT1 to Regulate Malignant Phenotype of Cancer Cell and Cytotoxic T Cell Infiltration via Epigenetic Inhibition of p53, cGAS, and STING in Lung Cancer,” Frontiers in Genetics 11 (2020): 250.

[44] A. Kallingal, M. Olszewski, N. Maciejewska, et al., “Cancer Immune Escape: The Role of Antigen Presentation Machinery,” Journal of Cancer Research and Clinical Oncology 149, no. 10 (2023): 8131–8141.

[45] S. Jhunjhunwala, C. Hammer, and L. Delamarre, “Antigen Presentation in Cancer: Insights Into Tumour Immunogenicity and Immune Evasion,” Nature Reviews Cancer 21, no. 5 (2021): 298–312.

[46] M. Montesion, K. Murugesan, and D. X. Jin, “Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response,” Cancer Discovery 11, no. 2 (2021): 282–292.

[47] J. Wang, Q. Lu, X. Chen, and I. Aifantis, “Targeting MHC-I Inhibitory Pathways for Cancer Immunotherapy,” Trends in Immunology 45, no. 3 (2024): 177–187.

[48] X. Wu, T. Li, R. Jiang, et al., “Targeting MHC-I Molecules for Cancer: Function, Mechanism, and Therapeutic Prospects,” Molecular Cancer 22, no. 1 (2023): 194.

[49] A. Mpakali and E. Stratikos, “The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy,” Cancers (Basel) 13, no. 1 (2021): 134.

[50] A. de Mingo Pulido, K. Hanggi, D. P. Celias, et al., “The Inhibitory Receptor TIM-3 Limits Activation of the cGAS-STING Pathway in Intra-Tumoral Dendritic Cells by Suppressing Extracellular DNA Uptake,” Immunity 54, no. 6 (2021): 1154–1167.e1157.

[51] H. Tsuchiya and G. Shiota, “Immune Evasion by Cancer Stem Cells,” Regenerative Therapy 17 (2021): 20–33.

[52] H. Matsushita, M. D. Vesely, D. C. Koboldt, et al., “Cancer Exome Analysis Reveals a T-Cell-Dependent Mechanism of Cancer Immunoediting,” Nature 482, no. 7385 (2012): 400–404.

[53] C. Ghosh, G. Luong, and Y. Sun, “A Snapshot of the PD-1/PD-L1 Pathway,” Journal of Cancer 12, no. 9 (2021): 2735–2746.

[54] L. V. Mejia-Guarnizo, P. S. Monroy-Camacho, A. D. Turizo-Smith, and J. A. Rodriguez-Garcia, “The Role of Immune Checkpoints in Antitumor Response: A Potential Antitumor Immunotherapy,” Frontiers in Immunology 14 (2023): 1298571.

[55] X. Lin, K. Kang, P. Chen, et al., “Regulatory Mechanisms of PD-1/PD-L1 in Cancers,” Molecular Cancer 23, no. 1 (2024): 108.

[56] K. Abiko, N. Matsumura, J. Hamanishi, et al., “IFN-Gamma From Lymphocytes Induces PD-L1 Expression and Promotes Progression of Ovarian Cancer,” British Journal of Cancer 112, no. 9 (2015): 1501–1509.

[57] M. Yi, M. Niu, L. Xu, et al., “Regulation of PD-L1 Expression in the Tumor Microenvironment,” Journal of Hematology & Oncology 14, no. 1 (2021): 10.

[58] B. Rowshanravan, N. Halliday, and D. M. Sansom, “CTLA-4: A Moving Target in Immunotherapy,” Blood 131, no. 1 (2018): 58–67.

[59] P. Azimnasab-Sorkhabi, M. Soltani-Asl, and J. R. Kfoury Junior, “Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) as an Undetermined Tool in Tumor Cells,” Human Cell 36, no. 4 (2023): 1225–1232.

[60] C. M. Fares, M. Van Allen E, and C. G. Drake, “Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?,” American Society of Clinical Oncology Educational Book 39 (2019): 147–164.

[61] S. Koyama, E. A. Akbay, Y. Y. Li, et al., “Adaptive Resistance to Therapeutic PD-1 Blockade Is Associated With Upregulation of Alternative Immune Checkpoints,” Nature Communications 7 (2016): 10501.

[62] N. A. Manieri, E. Y. Chiang, and J. L. T. Grogan, “A Key Inhibitor of the Cancer Immunity Cycle,” Trends in Immunology 38, no. 1 (2017): 20–28.

[63] W. A. Freed-Pastor, L. J. Lambert, Z. A. Ely, et al., “The CD155/TIGIT Axis Promotes and Maintains Immune Evasion in Neoantigen-Expressing Pancreatic Cancer,” Cancer Cell 39, no. 10 (2021): 1342–1360.e1314.

[64] X. Jia, B. Yan, X. Tian, et al., “CD47/SIRPalpha Pathway Mediates Cancer Immune Escape and Immunotherapy,” International Journal of Biological Sciences 17, no. 13 (2021): 3281–3287.

[65] J. Son, R. C. Hsieh, and H. Y. Lin, “Inhibition of the CD47-SIRPalpha Axis for Cancer Therapy: A Systematic Review and Meta-Analysis of Emerging Clinical Data,” Frontiers in Immunology 13 (2022): 1027235.

[66] M. Golkaram, F. Kuo, S. Gupta, et al., “Spatiotemporal Evolution of the Clear Cell Renal Cell Carcinoma Microenvironment Links Intra-Tumoral Heterogeneity to Immune Escape,” Genome Medicine 14, no. 1 (2022): 143.

[67] K. Chen, T. W. H. Shuen, and P. K. H. Chow, “The Association Between Tumour Heterogeneity and Immune Evasion Mechanisms in Hepatocellular Carcinoma and Its Clinical Implications,” British Journal of Cancer 131, no. 3 (2024): 420–429.

[68] P. R. Prasetyanti and J. P. Medema, “Intra-Tumor Heterogeneity From a Cancer Stem Cell Perspective,” Molecular cancer 16, no. 1 (2017): 41.

[69] D. R. Caswell and C. Swanton, “The Role of Tumour Heterogeneity and Clonal Cooperativity in Metastasis, Immune Evasion and Clinical Outcome,” BMC Medicine [Electronic Resource] 15, no. 1 (2017): 133.

[70] O. R. Colegio, N. Q. Chu, A. L. Szabo, et al., “Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid,” Nature 513, no. 7519 (2014): 559–563.

[71] Y. Lin, G. Yan, M. Wang, et al., “Crosstalk Between Lactic Acid and Immune Regulation and Its Value in the Diagnosis and Treatment of Liver Failure,” Open Life Sciences 18, no. 1 (2023): 20220636.

[72] R. Baghban, L. Roshangar, R. Jahanban-Esfahlan, et al., “Tumor Microenvironment Complexity and Therapeutic Implications at a Glance,” Cell Communication and Signaling 18, no. 1 (2020): 59.

[73] B. Cheng, Q. Yu, and W. Wang, “Intimate Communications Within the Tumor Microenvironment: Stromal Factors Function as an Orchestra,” Journal of Biomedical Science 30, no. 1 (2023): 1.

[74] K. Ma, L. Wang, W. Li, et al., “Turning Cold Into Hot: Emerging Strategies to Fire up the Tumor Microenvironment,” Trends in Cancer 11, no. 2 (2025): 117–134.

[75] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31–46.

[76] L. Arpinati G. Carradori, and R. Scherz-Shouval, “CAF-Induced Physical Constraints Controlling T Cell State and Localization in Solid Tumours,” Nature Reviews Cancer 24, no. 10 (2024): 676–693.

[77] L. Zhao, S. Jin, and S. Wang, “Tertiary Lymphoid Structures in Diseases: Immune Mechanisms and Therapeutic Advances,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 225.

[78] G. Ortiz-Munoz, M. Brown, C. B. Carbone, et al., “In Situ Tumour Arrays Reveal Early Environmental Control of Cancer Immunity,” Nature 618, no. 7966 (2023): 827–833.

[79] C. L. Gerard, J. Delyon, A. Wicky, et al., “Turning Tumors From Cold to Inflamed to Improve Immunotherapy Response,” Cancer Treatment Reviews 101 (2021): 102227.

[80] U. Basak, T. Sarkar, S. Mukherjee, et al., “Tumor-Associated Macrophages: An Effective Player of the Tumor Microenvironment,” Frontiers in Immunology 14 (2023): 1295257.

[81] Y. Zhu, Z. Zhou, X. Du, et al., “Cancer Cell-Derived Arginine Fuels Polyamine Biosynthesis in Tumor-Associated Macrophages to Promote Immune Evasion,” Cancer Cell 43, no. 6 (2025): 1045–1060.e1047.

[82] T. F. Gajewski, “Innate and Adaptive Immune Cells in Tumor Microenvironment,” Gulf Journal of Oncology 1, no. 35 (2021): 77–81.

[83] S. Chen, J. Chen, Y. Kong, et al., “Knockdown of TIM3 Hampers Dendritic Cell Maturation and Induces Immune Suppression by Modulating T-Cell Responses,” International Journal of Molecular Sciences 26, no. 9 (2025): 4332.

[84] B. Xie, B. Yuan, X. Zhao, et al., “Ms4a7 Expression in cDC1s Determines Cross-Presentation and Antitumor Immunity,” Science 390, no. 6774 (2025): eady5362.

[85] Z. Zhang and C. Zhang, “Regulation of cGAS-STING Signalling and Its Diversity of Cellular Outcomes,” Nature Reviews Immunology 25, no. 6 (2025): 425–444.

[86] B. Zhang, P. Xu, and A. Ablasser, “Regulation of the cGAS-STING Pathway,” Annual Review of Immunology 43, no. 1 (2025): 667–692.

[87] A. Teijeira, S. Garasa, C. Luri-Rey, et al., “Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy,” Cancer Research 82, no. 23 (2022): 4373–4385.

[88] N. Mikami, R. Kawakami, A. Sugimoto, et al., “Generating Functionally Stable and Antigen-Specific T(reg) Cells From Effector T Cells for Cell Therapy of Inflammatory Diseases,” Science Translational Medicine 17, no. 821 (2025): eadr6049.

[89] J. Cha, C. G. Kim, N. S. Sim, et al., “4-1BB(+) Tregs and Inhibitory Progenitor Exhausted T Cells Confer Resistance to Anti-PD-L1 and Anti-CTLA-4 Combination Therapy,” Cell Reports Medicine 6, no. 10 (2025): 102408.

[90] D. I. Gabrilovich and S. Nagaraj, “Myeloid-Derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology 9, no. 3 (2009): 162–174.

[91] Q. Liao, X. Zhou, L. Wu, et al., “Gut Microbial Metabolite 4-Hydroxybenzeneacetic Acid Drives Colorectal Cancer Progression via Accumulation of Immunosuppressive PMN-MDSCs,” Journal of Clinical Investigation 135, no. 11 (2025): e181243.

[92] C. Lee, J. Lee, M. Jeong, et al., “Emerging Strategies for Targeting Tumor-Associated Macrophages in Glioblastoma: A Focus on Chemotaxis Blockade,” Life Sciences 376 (2025): 123762.

[93] J. A. Grout, P. Sirven, A. M. Leader, et al., “Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-Cell Exclusion in Human Lung Tumors,” Cancer Discovery 12, no. 11 (2022): 2606–2625.

[94] R. S. Apte, D. S. Chen, and N. Ferrara, “VEGF in Signaling and Disease: Beyond Discovery and Development,” Cell 176, no. 6 (2019): 1248–1264.

[95] A. T. Krishnamurty, J. A. Shyer, M. Thai, et al., “LRRC15(+) Myofibroblasts Dictate the Stromal Setpoint to Suppress Tumour Immunity,” Nature 611, no. 7934 (2022): 148–154.

[96] Y. Du, J. Cao, X. Jiang, et al., “Comprehensive Analysis of CXCL12 Expression Reveals the Significance of Inflammatory Fibroblasts in Bladder Cancer Carcinogenesis and Progression,” Cancer Cell International 21, no. 1 (2021): 613.

[97] T. J. Harryvan, M. Visser, L. de Bruin, et al., “Enhanced Antigen Cross-Presentation in Human Colorectal Cancer-Associated Fibroblasts Through Upregulation of the Lysosomal Protease Cathepsin S,” Journal for ImmunoTherapy of Cancer 10, no. 3 (2022): e003591.

[98] M. A. Lakins, E. Ghorani, H. Munir, et al., “Cancer-Associated Fibroblasts Induce Antigen-Specific Deletion of CD8 (+) T Cells to Protect Tumour Cells,” Nature Communications 9, no. 1 (2018): 948.

[99] Z. Yuan, Y. Li, S. Zhang, et al., “Extracellular Matrix Remodeling in Tumor Progression and Immune Escape: From Mechanisms to Treatments,” Molecular Cancer 22, no. 1 (2023): 48.

[100] X. Yuan, W. Ruan, B. Bobrow, et al., “Targeting Hypoxia-Inducible Factors: Therapeutic Opportunities and Challenges,” Nature Reviews Drug Discovery 23, no. 3 (2024): 175–200.

[101] Y. Zhao, C. Xing, Y. Deng, et al., “HIF-1Alpha Signaling: Essential Roles in Tumorigenesis and Implications in Targeted Therapies,” Genes & Diseases 11, no. 1 (2024): 234–251.

[102] M. Vitale and M. Parodi, “Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?,” Vaccines (Basel) 9, no. 10 (2021): 1144.

[103] R. Sangsuwan, B. Thuamsang, N. Pacifici, et al., “Lactate Exposure Promotes Immunosuppressive Phenotypes in Innate Immune Cells,” Cellular and Molecular Bioengineering 13, no. 5 (2020): 541–557.

[104] H. Wu, V. Estrella, M. Beatty, et al., “T-Cells Produce Acidic Niches in Lymph Nodes to Suppress Their Own Effector Functions,” Nature Communications 11, no. 1 (2020): 4113.

[105] A. Khan, Y. Zhang, N. Ma, et al., “NF-KappaB Role on Tumor Proliferation, Migration, Invasion and Immune Escape,” Cancer Gene Therapy 31, no. 11 (2024): 1599–1610.

[106] D. V. F. Tauriello, E. Sancho, and E. Batlle, “Overcoming TGFbeta-Mediated Immune Evasion in Cancer,” Nature Reviews Cancer 22, no. 1 (2022): 25–44.

[107] A. C. Betzler, M. N. Theodoraki, and P. J. Schuler, “NF-KappaB and Its Role in Checkpoint Control,” International Journal of Molecular Sciences 21, no. 11 (2020): 3949.

[108] M. R. Walter, “The Molecular Basis of IL-10 Function: From Receptor Structure to the Onset of Signaling,” Current Topics in Microbiology and Immunology 380 (2014): 191–212.

[109] M. Tolomeo and A. Cascio, “The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy,” International Journal of Molecular Sciences 22, no. 2 (2021): 603.

[110] S. H. Lee, D. Lee, J. Choi, et al., “Spatial Dissection of Tumour Microenvironments in Gastric Cancers Reveals the Immunosuppressive Crosstalk Between CCL2+ Fibroblasts and STAT3-Activated Macrophages,” Gut 74, no. 5 (2025): 714–727.

[111] X. Cai, Y. H. Chiu, and Z. J. Chen, “The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling,” Molecular Cell 54, no. 2 (2014): 289–296.

[112] M. Z. Wu, W. C. Cheng, S. F. Chen, et al., “miR-25/93 Mediates Hypoxia-Induced Immunosuppression by Repressing cGAS,” Nature Cell Biology 19, no. 10 (2017): 1286–1296.

[113] S. W. Tse, K. McKinney, W. Walker, et al., “mRNA-Encoded, Constitutively Active STING(V155M) Is a Potent Genetic Adjuvant of Antigen-Specific CD8(+) T Cell Response,” Molecular Therapy 29, no. 7 (2021): 2227–2238.

[114] L. Pang, F. Zhou, Y. Liu, et al., “Epigenetic Regulation of Tumor Immunity,” Journal of Clinical Investigation 134, no. 12 (2024): e178540.

[115] G. Thacker, S. Henry, A. Nandi, et al., “Immature Natural Killer Cells Promote Progression of Triple-Negative Breast Cancer,” Science Translational Medicine 15, no. 686 (2023): eabl4414.

[116] B. Mlecnik, C. Bifulco, G. Bindea, et al., “Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer,” Journal of Clinical Oncology 38, no. 31 (2020): 3638–3651.

[117] D. M. Borras, S. Verbandt, M. Ausserhofer, et al., “Single Cell Dynamics of Tumor Specificity Vs Bystander Activity in CD8(+) T Cells Define the Diverse Immune Landscapes in Colorectal Cancer,” Cell Discovery 9, no. 1 (2023): 114.

[118] C. Ritter, K. Fan, A. Paschen, et al., “Epigenetic Priming Restores the HLA Class-I Antigen Processing Machinery Expression in Merkel Cell Carcinoma,” Scientific Reports 7, no. 1 (2017): 2290.

[119] Y. Tu, Q. Y. Zhu, W. J. Huang, et al., “DNMT Inhibition Epigenectically Restores the cGAS-STING Pathway and Activates RIG-I/MDA5-MAVS to Enhance Antitumor Immunity,” Acta Pharmacologica Sinica 47, no. 1 (2025): 197–208.

[120] V. Gambacorta, S. Beretta, M. Ciccimarra, et al., “Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse,” Cancer Discovery 12, no. 6 (2022): 1449–1461.

[121] H. Lin, I. Kryczek, S. Li, et al., “Stanniocalcin 1 Is a Phagocytosis Checkpoint Driving Tumor Immune Resistance,” Cancer Cell 39, no. 4 (2021): 480–493.

[122] J. Li, Z. Lan, W. Liao, et al., “Histone Demethylase KDM5D Upregulation Drives Sex Differences in Colon Cancer,” Nature 619, no. 7970 (2023): 632–639.

[123] G. K. Griffin, J. Wu, A. Iracheta-Vellve, et al., “Epigenetic Silencing by SETDB1 Suppresses Tumour Intrinsic Immunogenicity,” Nature 595, no. 7866 (2021): 309–314.

[124] D. V. Krysko, A. D. Garg, and A. Kaczmarek, “Immunogenic Cell Death and DAMPs in Cancer Therapy,” Nature Reviews Cancer 12, no. 12 (2012): 860–875.

[125] L. Galluzzi, E. Guilbaud, D. Schmidt, et al., “Targeting Immunogenic Cell Stress and Death for Cancer Therapy,” Natural Reviews Drug Discovery 23, no. 6 (2024): 445–460.

[126] R. Chen, J. Zou, J. Liu, et al., “DAMPs in the Immunogenicity of Cell Death,” Molecular Cell 85, no. 20 (2025): 3874–3889.

[127] S. N. Khleif and S. Gupta, “Cancer Vaccines as Enablers of Immunotherapy,” Nature Immunology 26, no. 11 (2025): 1877–1889.

[128] H. L. Kaufman, F. J. Kohlhapp, and A. Zloza, “Oncolytic Viruses: A New Class of Immunotherapy Drugs,” Natural Reviews Drug Discovery 15, no. 9 (2016): 660.

[129] X. Yu and S. He, “The Interplay Between Human Herpes Simplex Virus Infection and the Apoptosis and Necroptosis Cell Death Pathways,” Virology Journal 13 (2016): 77.

[130] R. H. Andtbacka, H. L. Kaufman, and F. Collichio, “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma,” Journal of Clinical Oncology 33, no. 25 (2015): 2780–2788.

[131] J. Gong, E. Sachdev, A. C. Mita, and M. M. Mita, “Clinical Development of Reovirus for Cancer Therapy: An Oncolytic Virus With Immune-Mediated Antitumor Activity,” World Journal of Methodology 6, no. 1 (2016): 25–42.

[132] J. Yang, J. Yan, and B. Liu, “Targeting VEGF/VEGFR to Modulate Antitumor Immunity,” Frontiers in Immunology 9 (2018): 978.

[133] P. E. de Almeida, J. Mak, G. Hernandez, et al., “Anti-VEGF Treatment Enhances CD8(+) T-Cell Antitumor Activity by Amplifying Hypoxia,” Cancer Immunology Research 8, no. 6 (2020): 806–818.

[134] X. Sun, B. Wu, H. C. Chiang, et al., “Tumour DDR1 Promotes Collagen Fibre Alignment to Instigate Immune Exclusion,” Nature 599, no. 7886 (2021): 673–678.

[135] S. Mariathasan, S. J. Turley, D. Nickles, et al., “TGFBeta Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells,” Nature 554, no. 7693 (2018): 544–548.

[136] D. V. F. Tauriello, S. Palomo-Ponce, D. Stork, et al., “TGFbeta Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis,” Nature 554, no. 7693 (2018): 538–543.

[137] N. Nagarsheth, M. S. Wicha, and W. Zou, “Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy,” Nature Reviews Immunology 17, no. 9 (2017): 559–572.

[138] K. M. Maalej, M. Merhi, V. P. Inchakalody, et al., “CAR-Cell Therapy in the Era of Solid Tumor Treatment: Current Challenges and Emerging Therapeutic Advances,” Molecular Cancer 22, no. 1 (2023): 20.

[139] S. Krishna, P. F. Robbins, F. J. Lowery, and S. A. Rosenberg, “Hallmarks and Correlates of Effective Adoptive Cell Immunotherapy for Cancer,” Nature Reviews Immunology, ahead of print, June 2, 2026, https://doi.org/10.1038/s41577-026-01312-3.

[140] E. N. Arner and J. C. Rathmell, “Metabolic Programming and Immune Suppression in the Tumor Microenvironment,” Cancer Cell 41, no. 3 (2023): 421–433.

[141] X. Ma, L. Xiao, L. Liu, et al., “CD36-Mediated Ferroptosis Dampens Intratumoral CD8(+) T Cell Effector Function and Impairs Their Antitumor Ability,” Cell Metabolism 33, no. 5 (2021): 1001–1012.e1005.

[142] H. Yu, J. Liu, X. Bu, et al., “Targeting METTL3 Reprograms the Tumor Microenvironment to Improve Cancer Immunotherapy,” Cell Chemical Biology 31, no. 4 (2024): 776–791.e777.

[143] B. L. Cadilha, M. R. Benmebarek, K. Dorman, et al., “Combined Tumor-Directed Recruitment and Protection From Immune Suppression Enable CAR T Cell Efficacy in Solid Tumors,” Science Advances 7, no. 24 (2021): eabi5781.

[144] Y. Xiao, T. J. Yu, Y. Xu, et al., “Emerging Therapies in Cancer Metabolism,” Cell Metabolism 35, no. 8 (2023): 1283–1303.

[145] M. P. Trefny, G. Kroemer, L. Zitvogel, and S. Kobold, “Metabolites as Agents and Targets for Cancer Immunotherapy,” Natural Reviews Drug Discovery 24, no. 10 (2025): 764–784.

[146] M. Arafat Hossain, “A Comprehensive Review of Immune Checkpoint Inhibitors for Cancer Treatment,” International Immunopharmacology 143, no. pt. 2 (2024): 113365.

[147] O. S. Qureshi, Y. Zheng, K. Nakamura, et al., “Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4,” Science 332, no. 6029 (2011): 600–603.

[148] A. J. Korman, S. C. Garrett-Thomson, and N. Lonberg, “The Foundations of Immune Checkpoint Blockade and the Ipilimumab Approval Decennial,” Natural Reviews Drug Discovery 21, no. 7 (2022): 509–528.

[149] L. Zhao, S. Cheng, L. Fan, et al., “TIM-3: An Update on Immunotherapy,” International Immunopharmacology 99 (2021): 107933.

[150] V. Aggarwal, C. J. Workman, and D. A. A. Vignali, “LAG-3 as the Third Checkpoint Inhibitor,” Nature Immunology 24, no. 9 (2023): 1415–1422.

[151] B. C. Cianciotti, Z. I. Magnani, A. Ugolini, et al., “TIM-3, LAG-3, or 2B4 Gene Disruptions Increase the Anti-Tumor Response of Engineered T Cells,” Frontiers in Immunology 15 (2024): 1315283.

[152] P. Zamani, E. Barootchi, A. Firouzabadi, et al., “Targeting T Cell Exhaustion in Colorectal Cancer: Emerging Roles of LAG-3, TIM-3, and TIGIT Signaling in Overcoming Immunotherapy Resistance,” Cell Communication and Signaling 24, no. 1 (2026): 81.

[153] L. L. Cao and J. C. Kagan, “Targeting Innate Immune Pathways for Cancer Immunotherapy,” Immunity 56, no. 10 (2023): 2206–2217.

[154] H. Zhu, Y. Lin, L. Jiang, et al., “DJ-1 Inhibition Reshapes Tumor Microenvironment and Potentiates Immune Checkpoint Inhibitors,” Science Advances 12, no. 15 (2026): eady7556.

[155] X. Zhang, Y. Gao, W. Hu, et al., “Reactivating Exhausted Tumor-Infiltrating T Cells by a Bispecific DC-T Cell Engager in Mice,” Nature Communications 17, no. 1 (2026): 4081.

[156] K. Okuyama, T. Naruse, Y. Matsushita, et al., “Precision Immunotherapy for Head and Neck Cancer: Therapeutic Combinations, Biomarker Strategies, and Translational Challenges,” Molecular Cancer 25, no. 1 (2026): 120.

[157] M. Wan, J. Mei, Y. Cai, et al., “Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple-Negative Breast Cancer,” Advanced Science (Weinheim) 12, no. 39 (2025): e01341.

[158] Y. Jiang, Y. Zheng, Y. W. Zhang, et al., “Reciprocal Inhibition Between TP63 and STAT1 Regulates Anti-Tumor Immune Response Through Interferon-Gamma Signaling in Squamous Cancer,” Nature Communications 15, no. 1 (2024): 2484.

[159] Q. Mu, H. Deng, S. Li, et al., “A Biomimetic Nanodisc System Selectively Activates Type I Interferons by Nonclassical STING Pathway for Cancer Immunotherapy,” Nature Communications 17 (2026): 6146, https://doi.org/10.1038/s41467-026-71363-6.

[160] Y. Wang, A. Zhong, B. Wang, et al., “A Blood-Brain Barrier-Like Vascular Gate Limits Immunotherapy Efficacy in Neuroendocrine Cancers,” Cell 189, no. 13 (2026): 3922–3939.

[161] J. Gu, Y. Li, Q. Chen, et al., “Tumor-Produced Ammonia Is Metabolized by Regulatory T Cells to Further Impede Anti-Tumor Immunity,” Cell 189, no. 2 (2026): 418–434.e424.

[162] J. J. Ni, Z. Z. Zhang, M. J. Ge, et al., “Immune-Based Combination Therapy to Convert Immunologically Cold Tumors Into Hot Tumors: An Update and New Insights,” Acta Pharmacologica Sinica 44, no. 2 (2023): 288–307.

[163] B. Olson, Y. Li, Y. Lin, et al., “Mouse Models for Cancer Immunotherapy Research,” Cancer Discovery 8, no. 11 (2018): 1358–1365.

[164] T. Courau, R. G. Jaszczak, B. Samad, et al., “Differential Assembly of Mouse and Human Tumor Microenvironments,” Nature Immunology 27, no. 6 (2026): 1282–1293.

[165] Z. Sethna, P. Guasp, C. Reiche, et al., “RNA Neoantigen Vaccines Prime Long-Lived CD8(+) T Cells in Pancreatic Cancer,” Nature 639, no. 8056 (2025): 1042–1051.

[166] H. Zhang, Y. Liu, A. Lin, et al., “Re: A Neoantigen Vaccine Generates Antitumour Immunity in Renal Cell Carcinoma,” European Urology 88, no. 3 (2025): 313–314.

[167] V. Verma, R. K. Shrimali, S. Ahmad, et al., “PD-1 Blockade in Subprimed CD8 Cells Induces Dysfunctional PD-1(+)CD38(hi) Cells and Anti-PD-1 Resistance,” Nature Immunology 20, no. 9 (2019): 1231–1243.

[168] T. A. Gonda, J. Fang, M. Salas, et al., “A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer,” Cancer Research 80, no. 21 (2020): 4754–4767.

[169] J. S. Weber, M. S. Carlino, A. Khattak, et al., “Individualised Neoantigen Therapy mRNA-4157 (V940) Plus Pembrolizumab Versus Pembrolizumab Monotherapy in Resected Melanoma (KEYNOTE-942): A Randomised, Phase 2b Study,” Lancet 403, no. 10427 (2024): 632–644.

[170] M. Yarchoan, E. J. Gane, T. U. Marron, et al., “Personalized Neoantigen Vaccine and Pembrolizumab in Advanced Hepatocellular Carcinoma: A Phase 1/2 Trial,” Nature Medicine 30, no. 4 (2024): 1044–1053.

[171] M. C. Garassino, S. Gadgeel, G. Speranza, et al., “Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study,” Journal of Clinical Oncology 41, no. 11 (2023): 1992–1998.

[172] M. Nishio, F. Barlesi, H. West, et al., “Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpower132 Trial,” Journal of Thoracic Oncology 16, no. 4 (2021): 653–664.

[173] M. C. Garassino, J. Mazieres, M. Reck, et al., “Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial,” Journal of Thoracic Oncology 17, no. 12 (2022): 1415–1427.

[174] W. Chang, M. D. Altman, C. A. Lesburg, et al., “Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer,” Journal of Medicinal Chemistry 65, no. 7 (2022): 5675–5689.

[175] J. Ye, B. N. Mills, and S. S. Qin, “Toll-Like Receptor 7/8 Agonist R848 Alters the Immune Tumor Microenvironment and Enhances SBRT-Induced Antitumor Efficacy in Murine Models of Pancreatic Cancer,” Journal for ImmunoTherapy of Cancer 10, no. 7 (2022): e004784.

[176] L. Hammerich, T. U. Marron, R. Upadhyay, et al., “Systemic Clinical Tumor Regressions and Potentiation of PD1 Blockade With In Situ Vaccination,” Nature Medicine 25, no. 5 (2019): 814–824.

[177] C. M. Kelly, C. R. Antonescu, T. Bowler, et al., “Objective Response Rate among Patients with Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination with Pembrolizumab: A Phase 2 Clinical Trial,” JAMA Oncology 6, no. 3 (2020): 402–408.

[178] F. Nassiri, V. Patil, L. S. Yefet, et al., “Oncolytic DNX-2401 Virotherapy Plus Pembrolizumab in Recurrent Glioblastoma: A Phase 1/2 Trial,” Nature Medicine 29, no. 6 (2023): 1370–1378.

[179] J. Gallego Perez-Larraya, M. Garcia-Moure, and S. Labiano, “Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma,” New England Journal of Medicine 386, no. 26 (2022): 2471–2481.

[180] J. A. Chesney, A. Ribas, G. V. Long, et al., “Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma,” Journal of Clinical Oncology 41, no. 3 (2023): 528–540.

[181] I. Heidegger, G. Fotakis, A. Offermann, et al., “Comprehensive Characterization of the Prostate Tumor Microenvironment Identifies CXCR4/CXCL12 Crosstalk as a Novel Antiangiogenic Therapeutic Target in Prostate Cancer,” Molecular Cancer 21, no. 1 (2022): 132.

[182] J. H. Wang, Y. Q. Zheng, Z. Y. Qian, et al., “Peritumoural Adipose Tissue Drives Immune Evasion in Colorectal Cancer via Adipose-Mesenchymal Transformation,” Nature Cell Biology 28, no. 3 (2026): 581–595.

[183] J. Larkin, M. Oya, M. Martignoni, et al., “Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results From the JAVELIN Renal 100 Phase Ib Trial,” Oncologist 28, no. 4 (2023): 333–340.

[184] B. Bockorny, V. Semenisty, T. Macarulla, et al., “BL-8040, a CXCR4 Antagonist, in Combination With pembrolizumab and Chemotherapy for Pancreatic Cancer: The COMBAT Trial,” Nature Medicine 26, no. 6 (2020): 878–885.

[185] Z. C. Jin, J. J. Chen, and X. L. Zhu, “Immune Checkpoint Inhibitors and Anti-Vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2201): A Target Trial Emulation Study,” EClinicalMedicine 72 (2024): 102622.

[186] H. Y. Kuo, K. A. Khan, and R. S. Kerbel, “Antiangiogenic-Immune-Checkpoint Inhibitor Combinations: Lessons From Phase III Clinical Trials,” Nature Reviews Clinical Oncology 21, no. 6 (2024): 468–482.

[187] H. A. Tawbi, D. Schadendorf, E. J. Lipson, et al., “Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma,” New England Journal of Medicine 386, no. 1 (2022): 24–34.

[188] Y. Lv, Z. Li, S. Liu, et al., “Metabolic Checkpoints in Immune Cell Reprogramming: Rewiring Immunometabolism for Cancer Therapy,” Molecular Cancer 24, no. 1 (2025): 210.

[189] L. Zhao, G. Zhao, J. Feng, et al., “T Cell Engineering for Cancer Immunotherapy by Manipulating Mechanosensitive Force-Bearing Receptors,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1220074.

[190] M. Schuler, K. Cuppens, T. Plones, et al., “Neoadjuvant Nivolumab With or Without Relatlimab in Resectable Non-Small-Cell Lung Cancer: A Randomized Phase 2 Trial,” Nature Medicine 30, no. 6 (2024): 1602–1611.

[191] D. B. Johnson, A. H. Nassar, A. Aijaz, et al., “Reconsidering Adjuvant and Perioperative Immune-Checkpoint Inhibition: De-Escalation, Expansion and Personalization,” Nature Reviews Clinical Oncology 23, no. 5 (2026): 341–355.

[192] K. Pang, Z. D. Shi, L. Y. Wei, et al., “Research Progress of Therapeutic Effects and Drug Resistance of Immunotherapy Based on PD-1/PD-L1 Blockade,” Drug Resistance Updates 66 (2023): 100907.

[193] S. Grabosch, M. Bulatovic, F. Zeng, et al., “Cisplatin-Induced Immune Modulation in Ovarian Cancer Mouse Models With Distinct Inflammation Profiles,” Oncogene 38, no. 13 (2019): 2380–2393.

[194] D. Liang, H. Xiao-Feng, and D. Guan-Jun, “Activated STING Enhances Tregs Infiltration in the HPV-Related Carcinogenesis of Tongue Squamous Cells via the c-jun/CCL22 Signal,” Biochimica et Biophysica Acta 1852, no. 11 (2015): 2494–2503.

[195] H. Kim, D. Sehgal, T. A. Kucaba, et al., “Acidic pH-Responsive Polymer Nanoparticles as a TLR7/8 Agonist Delivery Platform for Cancer Immunotherapy,” Nanoscale 10, no. 44 (2018): 20851–20862.

[196] W. M. Becicka, P. A. Bielecki, and M. E. Lorkowski, “The Effect of PEGylation on the Efficacy and Uptake of an Immunostimulatory Nanoparticle in the Tumor Immune Microenvironment,” Nanoscale Advances 3, no. 17 (2021): 4961–4972.

[197] K. Li, S. Qu, X. Chen, et al., “Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways,” International Journal of Molecular Sciences 18, no. 2 (2017): 404.

[198] L. A. Rojas, Z. Sethna, K. C. Soares, et al., “Personalized RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer,” Nature 618, no. 7963 (2023): 144–150.

[199] D. A. Braun, G. Moranzoni, V. Chea, et al., “A Neoantigen Vaccine Generates Antitumour Immunity in Renal Cell Carcinoma,” Nature 639, no. 8054 (2025): 474–482.

[200] O. Y. Revach, A. M. Cicerchia, O. Shorer, et al., “Overcoming Resistance to Immunotherapy by Targeting CD38 in Human Tumor Explants,” Cell Reports Medicine 6, no. 7 (2025): 102210.

[201] D. B. Keskin, A. J. Anandappa, J. Sun, et al., “Neoantigen Vaccine Generates Intratumoral T Cell Responses in Phase Ib Glioblastoma Trial,” Nature 565, no. 7738 (2019): 234–239.

[202] F. Meric-Bernstam, R. F. Sweis, F. S. Hodi, et al., “Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas,” Clinical Cancer Research 28, no. 4 (2022): 677–688.

[203] O. E. Rahma, V. E. Herrin, and R. A. Ibrahim, “Pre-Immature Dendritic Cells (PIDC) Pulsed With HPV16 E6 or E7 Peptide Are Capable of Eliciting Specific Immune Response in Patients With Advanced Cervical Cancer,” Journal of Translational Medicine 12 (2014): 353.

[204] N. Dubois Cauwelaert, A. L. Desbien, T. E. Hudson, et al., “The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction,” PLoS ONE 11, no. 1 (2016): e0146372.

[205] A. W. Silk, S. J. O'Day, and H. L. Kaufman, “A Phase 1b Single-Arm Trial of Intratumoral Oncolytic Virus V937 in Combination With Pembrolizumab in Patients With Advanced Melanoma: Results From the CAPRA Study,” Cancer Immunology, Immunotherapy 72, no. 6 (2023): 1405–1415.

[206] J. Fucikova, O. Kepp, L. Kasikova, et al., “Detection of Immunogenic Cell Death and Its Relevance for Cancer Therapy,” Cell Death & Disease 11, no. 11 (2020): 1013.

[207] S. Alanee, S. Sana, A. El-Zawahry, et al., “Phase I Trial of Intravesical Bacillus Calmette-Guerin Combined With Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer After Previous Bacillus Calmette-Guerin Treatment,” World Journal of Urology 39, no. 10 (2021): 3807–3813.

[208] S. Z. Shalhout, D. M. Miller, K. S. Emerick, and H. L. Kaufman, “Therapy With Oncolytic Viruses: Progress and Challenges,” Nature Reviews Clinical Oncology 20, no. 3 (2023): 160–177.

[209] T. Zhao, T. Wei, J. Guo, et al., “PD-1-siRNA Delivered by Attenuated Salmonella Enhances the Antimelanoma Effect of Pimozide,” Cell Death & Disease 10, no. 3 (2019): 164.

[210] S. Han, X. Bao, Y. Zou, et al., “D-Lactate Modulates M2 Tumor-Associated Macrophages and Remodels Immunosuppressive Tumor Microenvironment for Hepatocellular Carcinoma,” Science Advances 9, no. 29 (2023): eadg2697.

[211] D. Peng, I. Kryczek, N. Nagarsheth, et al., “Epigenetic Silencing of TH1-Type Chemokines Shapes Tumour Immunity and Immunotherapy,” Nature 527, no. 7577 (2015): 249–253.

[212] D. Roulois, H. Loo Yau, and R. Singhania, “DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts,” Cell 162, no. 5 (2015): 961–973.

[213] M. L. Burr, C. E. Sparbier, and K. L. Chan, “An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer,” Cancer Cell 36, no. 4 (2019): 385–401.e388.

[214] E. Giampazolias, O. Schulz, K. H. J. Lim, et al., “Secreted Gelsolin Inhibits DNGR-1-Dependent Cross-Presentation and Cancer Immunity,” Cell 184, no. 15 (2021): 4016–4031.e4022.

[215] L. Wang, X. Dou, S. Chen, et al., “YTHDF2 Inhibition Potentiates Radiotherapy Antitumor Efficacy,” Cancer Cell 41, no. 7 (2023): 1294–1308.e1298.

[216] H. Chen, Y. Pan, Q. Zhou, et al., “METTL3 Inhibits Antitumor Immunity by Targeting M(6)A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer,” Gastroenterology 163, no. 4 (2022): 891–907.

[217] X. Li, T. Yong, Z. Wei, et al., “Reversing Insufficient Photothermal Therapy-induced Tumor Relapse and Metastasis by Regulating Cancer-Associated Fibroblasts,” Nature Communications 13, no. 1 (2022): 2794.

[218] A. Nicolas-Boluda, J. Vaquero, and L. Vimeux, “Tumor Stiffening Reversion Through Collagen Crosslinking Inhibition Improves T Cell Migration and Anti-PD-1 Treatment,” Elife 10 (2021): e58688.

[219] D. Fukumura, J. Kloepper, Z. Amoozgar, et al., “Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges,” Nature Reviews Clinical Oncology 15, no. 5 (2018): 325–340.

[220] R. S. Finn, S. Qin, and M. Ikeda, “Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma,” New England Journal of Medicine 382, no. 20 (2020): 1894–1905.

[221] P. S. Hegde and D. S. Chen, “Top 10 Challenges in Cancer Immunotherapy,” Immunity 52, no. 1 (2020): 17–35.

[222] Y. Haku, K. Kitaoka, K. Ichimaru, et al., “Active Aldehydes Accelerate CD8(+) T Cell Exhaustion by Metabolic Alteration in the Tumor Microenvironment,” Nature Immunology 27, no. 2 (2026): 281–294.

[223] C. D. M. Alicea Pauneto, B. P. Riesenberg, and E. J. Gandy, “Intra-Tumoral Hypoxia Promotes CD8(+) T Cell Dysfunction via Chronic Activation of Integrated Stress Response Transcription Factor ATF4,” Immunity 58, no. 10 (2025): 2489–2504.e2488.

[224] L. Xia, L. Oyang, J. Lin, et al., “The Cancer Metabolic Reprogramming and Immune Response,” Molecular Cancer 20, no. 1 (2021): 28.

[225] S. Jin, E. Yin, C. Feng, et al., “Regulating Tumor Glycometabolism and the Immune Microenvironment by Inhibiting Lactate Dehydrogenase With Platinum(IV) Complexes,” Chemical Science 14, no. 31 (2023): 8327–8337.

[226] C. Niveau, M. Cettour-Cave, S. Mouret, et al., “MCT1 Lactate Transporter Blockade Re-Invigorates Anti-Tumor Immunity Through Metabolic Rewiring of Dendritic Cells in Melanoma,” Nature Communications 16, no. 1 (2025): 1083.

[227] J. Liu, X. Cai, J. Lin, et al., “Extracellular GPX4 Impairs Antitumor Immunity via Dendritic ZP3 Receptors,” Cell 189, no. 4 (2026): 1056–1073.e1024.

[228] Y. Qin, F. Huo, Z. Feng, et al., “CD36 Promotes Iron Accumulation and Dysfunction in CD8+ T Cells via the p38-CEBPB-TfR1 Axis in Early-Stage Hepatocellular Carcinoma,” Clinical and Molecular Hepatology 31, no. 3 (2025): 960–980.

[229] J. R. Giles, A. M. Globig, S. M. Kaech, and E. J. Wherry, “CD8(+) T Cells in the Cancer-Immunity Cycle,” Immunity 56, no. 10 (2023): 2231–2253.

[230] S. Lee and T. D. Kim, “Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mphi, and DC-Based Treatments,” International Journal of Molecular Sciences 24, no. 24 (2023): 17634.

[231] Y. Zhang and Z. Zhang, “The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications,” Cellular & Molecular Immunology 17, no. 8 (2020): 807–821.

[232] T. Zhang, Z. Tai, F. Miao, et al., “Adoptive Cell Therapy for Solid Tumors Beyond CAR-T: Current Challenges and Emerging Therapeutic Advances,” Journal of Control Release 368 (2024): 372–396.

[233] M. B. Dong, G. Wang, and R. D. Chow, “Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells,” Cell 178, no. 5 (2019): 1189–1204.e1123.

[234] J. Wei, L. Long, W. Zheng, et al., “Targeting REGNASE-1 Programs Long-Lived Effector T Cells for Cancer Therapy,” Nature 576, no. 7787 (2019): 471–476.

[235] Y. Liu, B. Debo, M. Li, et al., “LSD1 Inhibition Sustains T Cell Invigoration With a Durable Response to PD-1 Blockade,” Nature Communications 12, no. 1 (2021): 6831.

[236] T. M. Bauer, B. Besse, and A. Martinez-Marti, “Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC,” Journal of Thoracic Oncology 14, no. 10 (2019): 1828–1838.

[237] C. J. Imianowski, Q. Chen, C. J. Workman, and D. A. A. Vignali, “Regulatory T Cells in the Tumour Microenvironment,” Nature Reviews Cancer 25, no. 9 (2025): 703–722.

[238] B. Chen, W. Yao, X. Li, et al., “A Phase Ib/II Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Plus Anlotinib as First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer,” British Journal of Cancer 130, no. 3 (2024): 450–456.

[239] B. Long, H. Zhou, Z. Yu, et al., “Neoadjuvant Cadonilimab Plus FLOT Chemotherapy in Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A Multicenter, Phase 2 Study,” Med 6, no. 3 (2025): 100531.

[240] N. Niu, K. Li, J. Wang, et al., “Chemotherapy in Synergy With Innate Immune Agonists Enhances T Cell Priming for Checkpoint Inhibitor Treatment in Pancreatic Cancer,” Biomarker Research 13, no. 1 (2025): 21.

[241] J. C. Yang, S. M. Gadgeel, and L. V. Sequist, “Pembrolizumab in Combination with Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC with Sensitizing EGFR Mutation,” Journal of Thoracic Oncology 14, no. 3 (2019): 553–559.

[242] G. R. Oxnard, J. C. Yang, H. Yu, et al., “TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-Mutant Lung Cancer,” Annals of Oncology 31, no. 4 (2020): 507–516.

[243] R. Motzer, B. Alekseev, S. Y. Rha, et al., “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma,” New England Journal of Medicine 384, no. 14 (2021): 1289–1300.

[244] J. A. Tracz, B. M. Donnelly, S. Ngu, et al., “The Abscopal Effect: Inducing Immunogenicity in the Treatment of Brain Metastases Secondary to Lung Cancer and Melanoma,” Journal of Neuro-Oncology 163, no. 1 (2023): 1–14.

[245] M. A. Habibi, P. Delbari, F. Rashidi, et al., “The Clinical Benefit of Adding Radiotherapy to Ipilimumab in Patients With Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis,” Clinical & Experimental Metastasis 42, no. 2 (2025): 17.

[246] R. Nandre, V. Verma, P. Gaur, et al., “IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status,” Cancer Immunology Research 10, no. 5 (2022): 571–580.

[247] A. W. Pedersen, K. L. Kopp, M. H. Andersen, and M. B. Zocca, “Immunoregulatory Antigens-Novel Targets for Cancer Immunotherapy,” Chinese Clinical Oncology 7, no. 2 (2018): 19.

[248] J. W. Kjeldsen, C. L. Lorentzen, E. Martinenaite, et al., “A Phase 1/2 Trial of an Immune-Modulatory Vaccine Against IDO/PD-L1 in Combination With nivolumab in Metastatic Melanoma,” Nature Medicine 27, no. 12 (2021): 2212–2223.

[249] J. Niu, C. Maurice-Dror, and D. H. Lee, “First-in-Human Phase 1 Study of the Anti-TIGIT Antibody Vibostolimab as Monotherapy or With Pembrolizumab for Advanced Solid Tumors, Including Non-Small-Cell Lung Cancer,” Annals of Oncology 33, no. 2 (2022): 169–180.

[250] T. A. Yap, P. M. LoRusso, D. J. Wong, et al., “A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients With Advanced Cancer and PD-L1 Resistance,” Clinical Cancer Research 29, no. 5 (2023): 888–898.

[251] M. Wu, A. Wu, X. Zhang, et al., “Identification of a Novel Small-Molecule Inhibitor Targeting TIM-3 for Cancer Immunotherapy,” Biochemical Pharmacology 212 (2023): 115583.

[252] Z. Yin, H. Zhang, K. Zhang, et al., “Impacts of Combining PD-L1 Inhibitor and Radiotherapy on the Tumour Immune Microenvironment in a Mouse Model of Esophageal Squamous Cell Carcinoma,” BMC Cancer 25, no. 1 (2025): 474.

[253] C. Tang, Q. He, J. Feng, et al., “Portal Vein Tumour Thrombosis Radiotherapy Improves the Treatment Outcomes of Immunotherapy Plus bevacizumab in Hepatocellular Carcinoma: A Multicentre Real-World Analysis With Propensity Score Matching,” Frontiers in Immunology 14 (2023): 1254158.

[254] J. C. Hassel, T. E. Schank, H. Smetak, et al., “Evaluation of Radio-Immunotherapy Sequence on Immunological Responses and Clinical Outcomes in Patients With Melanoma Brain Metastases (ELEKTRA),” Oncoimmunology 11, no. 1 (2022): 2066609.

[255] E. Salvatori, L. Lione, M. Compagnone, et al., “Neoantigen Cancer Vaccine Augments Anti-CTLA-4 Efficacy,” NPJ Vaccines 7, no. 1 (2022): 15.

[256] L. Pusztai, C. Yau, D. M. Wolf, et al., “Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Trial,” Cancer Cell 39, no. 7 (2021): 989–998.e985.

[257] Y. K. Kang, L. T. Chen, M. H. Ryu, et al., “Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastro-Oesophageal Junction Cancer (ATTRACTION-4): A Randomised, Multicentre, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 23, no. 2 (2022): 234–247.

[258] F. Sinner, M. Pinter, B. Scheiner, et al., “Atezolizumab Plus Bevacizumab in Patients With Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience,” Cancers (Basel) 14, no. 23 (2022): 5966.

[259] E. Limagne, M. Thibaudin, L. Nuttin, et al., “Trifluridine/Tipiracil Plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages,” Cancer Immunology Research 7, no. 12 (2019): 1958–1969.

[260] T. S. Lau, L. K. Y. Chan, and G. C. W. Man, “Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis,” Cancer Immunology Research 8, no. 8 (2020): 1099–1111.

[261] T. Flieswasser, J. Van Loenhout, L. Freire Boullosa, et al., “Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer,” Cells 9, no. 6 (2020): 1474.

[262] H. Zhu, Y. Shan, K. Ge, et al., “Oxaliplatin Induces Immunogenic Cell Death in Hepatocellular Carcinoma Cells and Synergizes With Immune Checkpoint Blockade Therapy,” Cellular Oncology (Dordrecht) 43, no. 6 (2020): 1203–1214.

[263] D. R. Spigel, C. Faivre-Finn, and J. E. Gray, “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology 40, no. 12 (2022): 1301–1311.

[264] Q. Zhou, M. Chen, G. Wu, et al., “GEMSTONE-301: A Phase III Clinical Trial of CS1001 as Consolidation Therapy in Patients With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) Who Did Not Have Disease Progression After Prior Concurrent/Sequential Chemoradiotherapy,” Translational Lung Cancer Research 9, no. 5 (2020): 2008–2015.

[265] L. Wang, Y. Liu, W. Rong, et al., “The Role of Intraoperative Electron Radiotherapy in Centrally Located Hepatocellular Carcinomas Treated With Narrow-Margin (<1 cm) Hepatectomy: A Prospective, Phase 2 Study,” HepatoBiliary Surgery and Nutrition 11, no. 4 (2022): 515–529.

[266] L. Wang, K. Shen, Z. Gao, et al., “Melanoma Derived Exosomes Amplify Radiotherapy Induced Abscopal Effect via IRF7/I-IFN Axis in Macrophages,” Advanced Science (Weinheim) 11, no. 13 (2024): e2304991.

[267] M. Sasaki, M. Tanaka, Y. Kojima, et al., “Anti-Tumor Immunity Enhancement by Photodynamic Therapy With Talaporfin Sodium and Anti-Programmed Death 1 Antibody,” Molecular Therapy Oncolytics 28 (2023): 118–131.

[268] B. Hassannia, P. Vandenabeele, and T. Vanden Berghe, “Targeting Ferroptosis to Iron out Cancer,” Cancer Cell 35, no. 6 (2019): 830–849.

[269] Y. Tang, G. Cui, H. Liu, et al., “Converting “Cold” to “Hot”: Epigenetics Strategies to Improve Immune Therapy Effect by Regulating Tumor-Associated Immune Suppressive Cells,” Cancer Communications (London) 44, no. 6 (2024): 601–636.

[270] Y. Wang, R. Narasimamurthy, M. Qu, et al., “Circadian Regulation of Cancer Stem Cells and the Tumor Microenvironment During Metastasis,” Nature Cancer 5, no. 4 (2024): 546–556.

[271] X. Liu, T. Liu, L. Hu, et al., “Identification and Characterization of the Promoter of Cancer-Related Gene LOXL2,” Experimental Cell Research 387, no. 2 (2020): 111786.

[272] J. L. Chitty, M. Yam, L. Perryman, et al., “A First-in-Class Pan-lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic Cancer,” Nature Cancer 4, no. 9 (2023): 1326–1344.

[273] W. Shi, H. Tang, S. Tan, et al., “MMA-Induced LOXL2(+) PSCs Promote Linear ECM Alignment in the Aging Pancreas Leading to Pancreatic Cancer Progression,” Cell Death & Disease 16, no. 1 (2025): 419.

[274] Nivolumab for Resected Stage III or IV Melanoma at 9 Years New England Journal of Medicine 2026, 394(8): 832.

[275] Z. Zhang, M. Langenbach, S. Sagar, et al., “Efficacy of CTLA-4 Checkpoint Therapy Is Dependent on IL-21 Signaling to Mediate Cytotoxic Reprogramming of PD-1(+)CD8(+) T Cells,” Nature Immunology 26, no. 1 (2025): 92–104.

[276] G. V. Long, R. Dummer, O. Hamid, et al., “Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Randomised, Double-Blind Study,” Lancet Oncology 20, no. 8 (2019): 1083–1097.

[277] P. E. Hall, N. Ready, A. Johnston, et al., “Phase II Study of Arginine Deprivation Therapy with Pegargiminase in Patients with Relapsed Sensitive or Refractory Small-Cell Lung Cancer,” Clinical Lung Cancer 21, no. 6 (2020): 527–533.

[278] W. Wan and W. Liu, “STING Recruits WIPI2 for Autophagosome Formation,” Autophagy 20, no. 4 (2024): 928–929.

[279] C. H. Chung, C. Y. Lin, C. Y. Chen, et al., “Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer,” Advanced Science (Weinheim) 10, no. 15 (2023): e2204514.

[280] J. Meng, X. Yang, J. Huang, et al., “Ferroptosis-Enhanced Immunotherapy With an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma,” Advanced Science (Weinheim) 10, no. 20 (2023): e2300517.

[281] J. M. Hendricks, C. E. Doubravsky, and E. Wehri, “Identification of Structurally Diverse FSP1 Inhibitors That Sensitize Cancer Cells to Ferroptosis,” Cell Chemical Biology 30, no. 9 (2023): 1090–1103.e1097.

[282] R. Rosa, J. Liu, C. Lu, et al., “Current State of CAR-T Cell Therapies for Solid Tumors,” Med 7, no. 5 (2026): 101028.

[283] G. Escobar, T. R. Berger, and M. V. Maus, “CAR-T Cells in Solid Tumors: Challenges and Breakthroughs,” Cell Reports Medicine 6, no. 11 (2025): 102353.

[284] P. Vishwasrao, G. Li, J. C. Boucher, et al., “Emerging CAR T Cell Strategies for the Treatment of AML,” Cancers (Basel) 14, no. 5 (2022): 1241.

[285] X. Yu, L. Song, L. Cen, et al., “Pan-Cancer Gammadelta TCR Analysis Uncovers Clonotype Diversity and Prognostic Potential,” Cell Reports Medicine 5, no. 10 (2024): 101764.

[286] A. P. Teixeira, D. Aubel, and M. Fussenegger, “Next-Generation Programmable Cell Therapies for Precision Medicine,” Nature Reviews Genetics 27 (2026): 585–602, https://doi.org/10.1038/s41576-026-00945-3.

[287] D. Davar, A. K. Dzutsev, J. A. McCulloch, et al., “Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients,” Science 371, no. 6529 (2021): 595–602.

[288] X. Kang, H. C. Lau, and J. Yu, “Modulating Gut Microbiome in Cancer Immunotherapy: Harnessing Microbes to Enhance Treatment Efficacy,” Cell Reports Medicine 5, no. 4 (2024): 101478.

[289] R. P. Tobin, D. T. Cogswell, V. M. Cates, et al., “Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma,” Clinical Cancer Research 29, no. 7 (2023): 1209–1219.

[290] N. Zhou, Z. Ling, X. Cao, et al., “IDO1 Regulating ROS Rhythm Reveals Glycogenolysis/PPP as a Cancer Treatment Target,” Nature Chemical Biology (2026), https://doi.org/10.1038/s41589-026-02161-w.

[291] P. B. Tan, Y. L. Verschoor, J. G. van den Berg, et al., “Neoadjuvant Immunotherapy in Mismatch-Repair-Proficient Colon Cancers,” Nature 648, no. 8094 (2025): 726–735.

[292] A. M. Holder, A. Dedeilia, K. Sierra-Davidson, et al., “Defining Clinically Useful Biomarkers of Immune Checkpoint Inhibitors in Solid Tumours,” Nature Reviews Cancer 24, no. 7 (2024): 498–512.

[293] D. J. McGrail, P. G. Pilie, N. U. Rashid, et al., “High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response Across all Cancer Types,” Annals of Oncology 32, no. 5 (2021): 661–672.

[294] M. R. Strickland, E. M. Lander, M. K. Gibson, et al., “Gastroesophageal Adenocarcinomas with Defective Mismatch Repair: Current Knowledge and Clinical Management,” Journal of the National Comprehensive Cancer Network: JNCCN 22, no. 3 (2024): e237103.

[295] P. Vikas, H. Messersmith, C. Compton, et al., “Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline,” Journal of Clinical Oncology 41, no. 10 (2023): 1943–1948.

[296] R. Gallon, L. McCormick, A. Saetta, et al., “EMQN Best Practice Guidelines for Analysis and Reporting of Microsatellite Instability in Solid Tumours,” European Journal of Human Genetics 34, no. 1 (2026): 134–146.

[297] F. Czernilofsky, A. Mathioudaki, L. Jopp-Saile, et al., “Reprogramming of Stroma-Derived Chemokine Networks Drives the Loss of Tissue Organization in Nodal B Cell Lymphoma,” Nature Cancer 7, no. 3 (2026): 538–552.

[298] X. Tu, M. Tu, and J. Xu, “Clinical Application of Peripheral Blood Biomarkers for Solid Tumors,” MedComm 7, no. 3 (2020): e70654.

[299] B. Liu, Y. Zhang, D. Wang, et al., “Single-Cell Meta-Analyses Reveal Responses of Tumor-Reactive CXCL13(+) T Cells to Immune-Checkpoint Blockade,” Nature Cancer 3, no. 9 (2022): 1123–1136.

[300] S. V. Bratman, S. Y. C. Yang, M. A. J. Iafolla, et al., “Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumor Patients Treated With pembrolizumab,” Nature Cancer 1, no. 9 (2020): 873–881.

[301] A. Franken, M. Bila, A. Mechels, et al., “CD4(+) T Cell Activation Distinguishes Response to Anti-PD-L1+Anti-CTLA4 Therapy From Anti-PD-L1 Monotherapy,” Immunity 57, no. 3 (2024): 541–558.e547.

[302] S. W. Zhang, H. Wang, Y. Xiao, et al., “Sensory Neurons Drive Immune Exclusion by Stimulating a Dense Extracellular Matrix in the Breast Cancer Tumor Microenvironment,” Cell 189, no. 4 (2026): 1039–1055.e1020.

[303] G. Fan, T. Xie, L. Tang, et al., “The Co-Location of CD14+APOE+ Cells and MMP7+ Tumour Cells Contributed to Worse Immunotherapy Response in Non-Small Cell Lung Cancer,” Clinical and Translational Medicine 14, no. 9 (2024): e70009.

[304] Y. Zhong, C. Cai, T. Chen, et al., “PET/CT Based Cross-Modal Deep Learning Signature to Predict Occult Nodal Metastasis in Lung Cancer,” Nature Communications 14, no. 1 (2023): 7513.

[305] G. Wang, F. Ding, K. Chen, et al., “CT-Based Radiomics Nomogram to Predict Proliferative Hepatocellular Carcinoma and Explore the Tumor Microenvironment,” Journal of Translational Medicine 22, no. 1 (2024): 683.

[306] H. Tong, J. Sun, J. Fang, et al., “A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study,” Frontiers in Immunology 13 (2022): 859323.

[307] T. Liu, T. Huang, T. Ding, et al., “Leveraging Multi-Modal Foundation Models for Analysing Spatial Multi-Omic and Histopathology Data,” Nature Biomedical Engineering (2026), https://doi.org/10.1038/s41551-025-01602-6.

[308] A. Nazha, O. Elemento, S. Ahuja, et al., “Artificial Intelligence in Hematology,” Blood 146, no. 19 (2025): 2283–2292.

[309] A. Marabelle, M. Fakih, J. Lopez, et al., “Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study,” Lancet Oncology 21, no. 10 (2020): 1353–1365.

[310] Y. Wu, R. Xue, X. Luo, et al., “Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions,” MedComm 7, no. 3 (2020): e70638.

[311] S. Q. Zhou, L. N. Wang, L. F. Wu, et al., “Deep Learning-Assisted Tumor Radiomic Dynamics on MRI Predict Pathological Complete Response in HCC Undergoing Immune-Based Therapy Followed by Hepatectomy,” Hepatology 84, no. 2 (2026): 453–468, https://doi.org/10.1097/HEP.0000000000001724.

[312] J. Lv, D. X. Zheng, J. H. Liang, et al., “Risk-Adaptive Therapy Guided by Dynamic ctDNA in Nasopharyngeal Carcinoma,” Nature 652, no. 8110 (2026): 731–739.

[313] J. M. J. Valanarasu, H. Xu, N. Usuyama, et al., “Multimodal AI Generates Virtual Population for Tumor Microenvironment Modeling,” Cell 189, no. 2 (2026): 386–400.e319.

[314] E. Grassi, V. Vurchio, G. D. Cresswell, et al., “Heterogeneity and Evolution of DNA Mutation Rates in Microsatellite Stable Colorectal Cancer,” Science Translational Medicine 17, no. 799 (2025): eado1641.

[315] A. Taira, M. Aavikko, R. Katainen, et al., “Comprehensive Metabolomic and Epigenomic Characterization of Microsatellite Stable BRAF-Mutated Colorectal Cancer,” Oncogene 44, no. 22 (2025): 1718–1730.

[316] A. A. Davis and V. G. Patel, “The Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of all US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors,” Journal for ImmunoTherapy of Cancer 7, no. 1 (2019): 278.

[317] Q. Duan, H. Zhang, J. Zheng, and L. Zhang, “Turning Cold Into Hot: Firing up the Tumor Microenvironment,” Trends in Cancer 6, no. 7 (2020): 605–618.

[318] Y. Lotan, V. Krishna, W. M. Abuzeid, et al., “Predicting Response to Intravesical Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort,” Journal D urologie 213, no. 2 (2025): 192–204.

[319] V. Nimgaonkar, V. Krishna, V. Krishna, et al., “Development of an Artificial Intelligence-Derived Histologic Signature Associated With Adjuvant Gemcitabine Treatment Outcomes in Pancreatic Cancer,” Cell Reports Medicine 4, no. 4 (2023): 101013.

[320] S. Zheng, W. Wang, L. Shen, et al., “Tumor Battlefield Within Inflamed, Excluded or Desert Immune Phenotypes: The Mechanisms and Strategies,” Experimental Hematology & Oncology 13, no. 1 (2024): 80.

[321] J. R. M. Black, T. Karasaki, C. W. Abbott, et al., “Longitudinal Ultrasensitive ctDNA Monitoring for High-Resolution Lung Cancer Risk Prediction,” Cell 188, no. 25 (2025): 7083–7098.

[322] S. Dai, H. Zeng, Z. Liu, et al., “Intratumoral CXCL13(+)CD8(+)T Cell Infiltration Determines Poor Clinical Outcomes and Immunoevasive Contexture in Patients With Clear Cell Renal Cell Carcinoma,” Journal for ImmunoTherapy of Cancer 9, no. 2 (2021): e001823.

[323] J. Zhang, D. Huang, P. E. Saw, and E. Song, “Turning Cold Tumors Hot: From Molecular Mechanisms to Clinical Applications,” Trends in Immunology 43, no. 7 (2022): 523–545.

[324] Y. Liu, M. Wu, Y. Zhang, et al., “Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer,” Frontiers in Oncology 11 (2021): 657615.

[325] L. Dercle, B. Zhao, M. Gonen, et al., “Early Readout on Overall Survival of Patients with Melanoma Treated with Immunotherapy Using a Novel Imaging Analysis,” JAMA Oncology 8, no. 3 (2022): 385–392.

[326] L. Basler, H. S. Gabrys, S. A. Hogan, et al., “Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibition,” Clinical Cancer Research 26, no. 16 (2020): 4414–4425.

[327] G. Gao, T. Ma, T. Zhang, et al., “Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota,” Frontiers in Immunology 12 (2021): 772532.

[328] E. G. Hunt, K. E. Hurst, B. P. Riesenberg, et al., “Acetyl-CoA Carboxylase Obstructs CD8(+) T Cell Lipid Utilization in the Tumor Microenvironment,” Cell Metabolism 36, no. 5 (2024): 969–983.e910.

[329] S. Berry, N. A. Giraldo, B. F. Green, et al., “Analysis of Multispectral Imaging With the AstroPath Platform Informs Efficacy of PD-1 Blockade,” Science 372, no. 6547 (2021): eaba2609.

[330] J. Kong, D. Ha, J. Lee, et al., “Network-Based Machine Learning Approach to Predict Immunotherapy Response in Cancer Patients,” Nature Communications 13, no. 1 (2022): 3703.

[331] S. Baxi, A. Yang, and R. L. Gennarelli, “Immune-Related Adverse Events for Anti-PD-1 and Anti-PD-L1 Drugs: Systematic Review and Meta-analysis,” BMJ 360 (2018): k793.

[332] L. B. Tang, Y. L. Peng, J. Chen, et al., “Rechallenge With Immune-Checkpoint Inhibitors in Patients With Advanced-Stage Lung Cancer,” Nature Reviews Clinical Oncology 22, no. 8 (2025): 546–565.

[333] M. Ramos-Casals, J. R. Brahmer, M. K. Callahan, et al., “Immune-Related Adverse Events of Checkpoint Inhibitors,” Nature Reviews Disease Primers 6, no. 1 (2020): 38.

[334] D. C. Moore, J. B. Elmes, J. R. Arnall, et al., “PD-1/PD-L1 Inhibitor-Induced Immune Thrombocytopenia: A Pharmacovigilance Study and Systematic Review,” International Immunopharmacology 129 (2024): 111606.

[335] J. D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, et al., “Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma,” Journal of Clinical Oncology 40, no. 2 (2022): 127–137.

[336] K. Okuyama, T. Naruse, Y. Matsushita, et al., “Precision Immunotherapy for Head and Neck Cancer: Therapeutic Combinations, Biomarker Strategies, and Translational Challenges,” Molecular Cancer 25, no. 1 (2026): 120.

[337] J. Bourhis, A. Auperin, C. Borel, et al., “NIVOPOSTOP (GORTEC 2018-01): A Phase III Randomized Trial of Adjuvant Nivolumab Added to Radio-Chemotherapy in Patients With Resected Head and Neck Squamous Cell Carcinoma at High Risk of Relapse,” Journal of Clinical Oncology 43, no. 17_suppl. (2025): LBA2–LBA2.

[338] N. Y. Lee, R. L. Ferris, A. Psyrri, et al., “Avelumab Plus Standard-of-Care Chemoradiotherapy Versus Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Trial,” Lancet Oncology 22, no. 4 (2021): 450–462.

[339] J. P. Machiels, Y. Tao, L. Licitra, et al., “Pembrolizumab Plus Concurrent Chemoradiotherapy Versus Placebo Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-412): A Randomised, Double-Blind, Phase 3 Trial,” Lancet Oncology 25, no. 5 (2024): 572–587.

[340] T. Galicia-Carmona, E. Arango-Bravo, J. A. Serrano-Olvera, et al., “ADXS11-001 LM-LLO as Specific Immunotherapy in Cervical Cancer,” Human Vaccines & Immunotherapeutics 17, no. 8 (2021): 2617–2625.

[341] D. Galizia, S. Minei, A. Abbona, et al., “863P Microbiota and Cytokines Profile in Patients (pts) Affected by Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Treated With Immune Checkpoint Inhibitors (ICIs) ± Chemotherapy (CT) and Prebiotic Inulin in the PRINCESS Study,” Annals of Oncology 34 (2023): S560.

[342] X. X. Wang, Y. T. Liu, J. G. Ren, et al., “Salivary Microbiome Relates to Neoadjuvant Immunotherapy Response in OSCC,” Journal of Dental Research 103, no. 10 (2024): 988–998.

[343] S. Peng, M. Wu, Q. Yan, et al., “Disrupting EDEM3-Induced M2-Like Macrophage Trafficking by Glucose Restriction Overcomes Resistance to PD-1/PD-L1 Blockade,” Clinical and Translational Medicine 15, no. 1 (2025): e70161.

[344] S. J. Hogg, P. A. Beavis, M. A. Dawson, and R. W. Johnstone, “Targeting the Epigenetic Regulation of Antitumour Immunity,” Natural Reviews Drug Discovery 19, no. 11 (2020): 776–800.

[345] Y. Zhao, Y. He, W. Wang, et al., “Efficacy and Safety of Immune Checkpoint Inhibitors for Individuals With Advanced EGFR-Mutated Non-Small-Cell Lung Cancer Who Progressed on EGFR Tyrosine-Kinase Inhibitors: A Systematic Review, Meta-Analysis, and Network Meta-Analysis,” Lancet Oncology 25, no. 10 (2024): 1347–1356.

[346] M. H. Oh, I. H. Sun, L. Zhao, et al., “Targeting Glutamine Metabolism Enhances Tumor-Specific Immunity by Modulating Suppressive Myeloid Cells,” Journal of Clinical Investigation 130, no. 7 (2020): 3865–3884.

[347] N. Malli Cetinbas, T. Monnell, and J. Soomer-James, “Tumor Cell-Directed STING Agonist Antibody-Drug Conjugates Induce Type III Interferons and Anti-Tumor Innate Immune Responses,” Nature Communications 15, no. 1 (2024): 5842.

[348] L. Chen, M. Zuo, Q. Zhou, and Y. Wang, “Oncolytic Virotherapy in Cancer Treatment: Challenges and Optimization Prospects,” Frontiers in Immunology 14 (2023): 1308890.

[349] H. Yuan, X. Li, M. Yu, et al., “Injectable SF-Platform Orchestrates GPX4-Targeted Ferroptosis-Autophagy-Immunogenic Circuit for Overcoming Oxidative Resistance in Triple-Negative Breast Cancer,” Theranostics 15, no. 17 (2025): 8757–8778.

[350] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews Molecular Cell Biology 22, no. 4 (2021): 266–282.

[351] Z. Wu, L. Zhang, X. Mao, et al., “Ferrous Iron Metabolism Modulator for Immune Stress Regulation and Its Application in Skin Allograft Models,” Journal of the American Chemical Society 147, no. 29 (2025): 25325–25336.

[352] D. B. Johnson, B. D. Jakubovic, V. Sibaud, and M. E. Sise, “Balancing Cancer Immunotherapy Efficacy and Toxicity,” Journal of Allergy and Clinical Immunology: In Practice 8, no. 9 (2020): 2898–2906.

[353] S. Zhang, W. Peng, H. Wang, et al., “C1q(+) Tumor-Associated Macrophages Contribute to Immunosuppression Through Fatty Acid Metabolic Reprogramming in Malignant Pleural Effusion,” Journal for ImmunoTherapy of Cancer 11, no. 8 (2023): e007441.

[354] R. Colombo and J. R. Rich, “The Therapeutic Window of Antibody Drug Conjugates: A Dogma in Need of Revision,” Cancer Cell 40, no. 11 (2022): 1255–1263.

[355] Q. Yin, L. Wu, L. Han, et al., “Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Review,” Frontiers in Immunology 14 (2023): 1167975.

[356] S. M. Blum, S. J. Rouhani, and R. J. Sullivan, “Effects of Immune-Related Adverse Events (irAEs) and Their Treatment on Antitumor Immune Responses,” Immunological Reviews 318, no. 1 (2023): 167–178.

[357] E. A. T. Koch, A. Petzold, E. Dippel, et al., “Optimizing Immune Checkpoint Blockade in Metastatic Uveal Melanoma: Exploring the Association of Overall Survival and the Occurrence of Adverse Events,” Frontiers in Immunology 15 (2024): 1395225.

[358] O. J. Kennedy, M. Kicinski, S. Valpione, et al., “Prognostic and Predictive Value of Beta-Blockers in the EORTC 1325/KEYNOTE-054 Phase III Trial of Pembrolizumab Versus Placebo in Resected High-Risk Stage III Melanoma,” European Journal of Cancer 165 (2022): 97–112.

[359] F. Meric-Bernstam, R. F. Sweis, S. Kasper, et al., “Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study,” Clinical Cancer Research 29, no. 1 (2023): 110–121.

[360] Y. Yuan, A. Adam, C. Zhao, and H. Chen, “Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy,” Cancers (Basel) 13, no. 4 (2021): 663.

[361] X. Chu, W. Tian, Z. Wang, et al., “Co-Inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials,” Molecular Cancer 22, no. 1 (2023): 93.

[362] A. Di Federico, S. Stumpo, F. Mantuano, et al., “Long-Term Overall Survival With Dual CTLA-4 and PD-L1 or PD-1 Blockade and Biomarker-Based Subgroup Analyses in Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis,” Lancet Oncology 26, no. 11 (2025): 1443–1453.

[363] J. Fang, S. Zhong, T. Wang, et al., “Immune-Related Adverse Events Are a Potent Predictor of Post-Transplant Rejection in HCC: A Multicentre Retrospective Cohort Study,” Gut 75, no. 6 (2025): 1201–1210.

[364] B. C. Cho, D. R. Abreu, and M. Hussein, “Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezolizumab as a First-Line Treatment for PD-L1-Selected Non-Small-Cell Lung Cancer (CITYSCAPE): Primary and Follow-Up Analyses of a Randomised, Double-Blind, Phase 2 Study,” Lancet Oncology 23, no. 6 (2022): 781–792.

[365] E. Arriola, M. Gonzalez-Cao, M. Domine, et al., “Addition of Immune Checkpoint Inhibitors to Chemotherapy Vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis,” Oncology and Therapy 10, no. 1 (2022): 167–184.

[366] A. X. Zhu, A. R. Abbas, and M. R. de Galarreta, “Molecular Correlates of Clinical Response and Resistance to Atezolizumab in Combination With Bevacizumab in Advanced Hepatocellular Carcinoma,” Nature Medicine 28, no. 8 (2022): 1599–1611.

[367] H. Chen, H. Yang, L. Guo, and Q. Sun, “The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances,” MedComm 6, no. 10 (2020): e70412.

[368] G. L. Banna, M. A. Hassan, A. Signori, et al., “Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis,” JAMA Network Open 7, no. 4 (2024): e246837.

[369] S. Li, W. Yu, F. Xie, et al., “Neoadjuvant Therapy With Immune Checkpoint Blockade, Antiangiogenesis, and Chemotherapy for Locally Advanced Gastric Cancer,” Nature Communications 14, no. 1 (2023): 8.

[370] S. Yu and J. Feng, “Comment on ″Durvalumab after Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial,” Journal of Thoracic Oncology 19, no. 1 (2024): 173–174.

[371] R. Ye, S. Li, Y. Li, et al., “Revealing the Role of Regulatory b Cells in Cancer: Development, Function and Treatment Significance,” Cancer Immunology, Immunotherapy 74, no. 4 (2025): 125.

[372] U. Uslu, L. Sun, S. Castelli, et al., “The STING Agonist IMSA101 Enhances Chimeric Antigen Receptor T Cell Function by Inducing IL-18 Secretion,” Nature Communications 15, no. 1 (2024): 3933.

[373] G. J. Roboz, K. Yee, A. Verma, et al., “Phase I Trials of the Lysine-Specific Demethylase 1 Inhibitor, GSK2879552, as Mono- and Combination-Therapy in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,” Leukemia & Lymphoma 63, no. 2 (2022): 463–467.

[374] E. L. Dane, A. Belessiotis-Richards, C. Backlund, et al., “STING Agonist Delivery by Tumour-Penetrating PEG-Lipid Nanodiscs Primes Robust Anticancer Immunity,” Nature Materials 21, no. 6 (2022): 710–720.

[375] S. Wang, V. Bohnert, A. J. Joseph, et al., “ENPP1 is an Innate Immune Checkpoint of the Anticancer cGAMP-STING Pathway in Breast Cancer,” PNAS 120, no. 52 (2023): e2313693120.

[376] J. A. Carozza, V. Bohnert, K. C. Nguyen, et al., “Extracellular cGAMP Is a Cancer Cell-Produced Immunotransmitter Involved in Radiation-Induced Anti-Cancer Immunity,” Nature Cancer 1, no. 2 (2020): 184–196.

[377] H. Liu, H. Zhang, X. Wu, et al., “Nuclear cGAS Suppresses DNA Repair and Promotes Tumorigenesis,” Nature 563, no. 7729 (2018): 131–136.

[378] B. Wiernicki, S. Maschalidi, J. Pinney, et al., “Cancer Cells Dying From Ferroptosis Impede Dendritic Cell-Mediated Anti-Tumor Immunity,” Nature Communications 13, no. 1 (2022): 3676.

[379] A. Kappler, C. Bryce, M. Mansor, et al., “An Evolving View on Biogeochemical Cycling of Iron,” Nature Reviews Microbiology 19, no. 6 (2021): 360–374.

[380] L. Ye, X. Wen, J. Qin, et al., “Metabolism-Regulated Ferroptosis in Cancer Progression and Therapy,” Cell Death & Disease 15, no. 3 (2024): 196.

[381] C. Conche, F. Finkelmeier, M. Pesic, et al., “Combining Ferroptosis Induction With MDSC Blockade Renders Primary Tumours and Metastases in Liver Sensitive to Immune Checkpoint Blockade,” Gut 72, no. 9 (2023): 1774–1782.

[382] M. Escobar-Rosales, C. Montaner, M. Exposit, et al., “De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders,” Journal of the American Chemical Society 147, no. 49 (2025): 45495–45505.

[383] D. Kang, A. Pandey, G. Kumar, et al., “A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention,” ACS Central Science 12, no. 5 (2026): 719–730.

[384] E. Fountzilas, A. M. Tsimberidou, and R. Kurzrock, “Patient Rights in Precision Oncology: Right Treatment, Right Time, Right Dose, Right Order, Right Place,” Genome Medicine 17, no. 1 (2025): 53.

[385] I. Mellman, D. S. Chen, T. Powles, and S. J. Turley, “The Cancer-Immunity Cycle: Indication, Genotype, and Immunotype,” Immunity 56, no. 10 (2023): 2188–2205.

[386] A. Baysoy, Z. Bai, R. Satija, and R. Fan, “The Technological Landscape and Applications of Single-Cell Multi-Omics,” Nature Reviews Molecular Cell Biology 24, no. 10 (2023): 695–713.

[387] S. Lee, G. Kim, J. Lee, et al., “Mapping Cancer Biology in Space: Applications and Perspectives on Spatial Omics for Oncology,” Molecular Cancer 23, no. 1 (2024): 26.

[388] N. Y. Li, W. Zhang, D. Haensel, et al., “Basal-to-Inflammatory Transition and Tumor Resistance via Crosstalk With a Pro-Inflammatory Stromal Niche,” Nature Communications 15, no. 1 (2024): 8134.

[389] Y. Zhang, Y. Guo, Z. Liu, et al., “Cancer Cells Co-Opt an Inter-Organ Neuroimmune Circuit to Escape Immune Surveillance,” Cell 188, no. 24 (2025): 6754–6773.e6729.

[390] Y. Deng, Z. Peng, K. Ming, et al., “Single-Cell Analysis of Human Thymus and Peripheral Blood Unveils the Dynamics of T Cell Development and Aging,” Nature Aging 5, no. 12 (2025): 2494–2513.

[391] J. K. Benotmane, J. Kueckelhaus, P. Will, et al., “High-Sensitive Spatially Resolved T Cell Receptor Sequencing With SPTCR-seq,” Nature Communications 14, no. 1 (2023): 7432.

[392] L. Magre, M. M. A. Verstegen, S. Buschow, et al., “Emerging Organoid-Immune Co-Culture Models for Cancer Research: From Oncoimmunology to Personalized Immunotherapies,” Journal for ImmunoTherapy of Cancer 11, no. 5 (2023): e006290.

[393] Q. Meng, S. Xie, G. K. Gray, et al., “Empirical Identification and Validation of Tumor-Targeting T Cell Receptors From Circulation Using Autologous Pancreatic Tumor Organoids,” Journal for ImmunoTherapy of Cancer 9, no. 11 (2021): e003213.

[394] E. Alemzadeh, L. Allahqoli, H. Dehghan, et al., “Circulating Tumor Cells and Circulating Tumor DNA in Breast Cancer Diagnosis and Monitoring,” Oncology Research 31, no. 5 (2023): 667–675.

[395] J. Zhao, H. Wang, C. Wang, et al., “Single-Cell Data-Driven Design of Armed Oncolytic Virus to Boost Cooperative Innate-Adaptive Immunity Against Cancer,” Molecular Therapy 33, no. 2 (2025): 703–722.

[396] M. Cavazzana, F. D. Bushman, A. Miccio, et al., “Gene Therapy Targeting Haematopoietic Stem Cells for Inherited Diseases: Progress and Challenges,” Natural Reviews Drug Discovery 18, no. 6 (2019): 447–462.

[397] G. Ferrari, A. J. Thrasher, and A. Aiuti, “Gene Therapy Using Haematopoietic Stem and Progenitor Cells,” Nature Reviews Genetics 22, no. 4 (2021): 216–234.

[398] D. Shi, S. Toyonaga, and D. G. Anderson, “In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles,” Nano Letters 23, no. 7 (2023): 2938–2944.

[399] C. Wang, Y. Xue, T. Markovic, et al., “Blood-Brain-Barrier-Crossing Lipid Nanoparticles for mRNA Delivery to the Central Nervous System,” Nature Materials 24, no. 10 (2025): 1653–1663.

[400] R. G. Lee, A. M. Mazzola, M. C. Braun, et al., “Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models,” Circulation 147, no. 3 (2023): 242–253.

[401] P. Germino-Watnick, M. Hinds, A. Le, et al., “Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease,” Cells 11, no. 11 (2022): 1843.

[402] M. C. Gundry, L. Brunetti, and A. Lin, “Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9,” Cell Reports 17, no. 5 (2016): 1453–1461.

[403] D. Tarab-Ravski, I. Hazan-Halevy, M. Goldsmith, et al., “Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles,” Advanced Science (Weinheim) 10, no. 21 (2023): e2301377.

[404] S. Gujar, J. G. Pol, V. Kumar, et al., “Tutorial: Design, Production and Testing of Oncolytic Viruses for Cancer Immunotherapy,” Nature Protocols 19, no. 9 (2024): 2540–2570.

[405] Y. Kim, P. Konda, J. P. Murphy, et al., “Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-Induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities,” Molecular & Cellular Proteomics 21, no. 2 (2022): 100182.

[406] L. Chen, Z. Ma, C. Xu, et al., “Progress in Oncolytic Viruses Modified With Nanomaterials for Intravenous Application,” Cancer Biology & Medicine 20, no. 11 (2023): 830–855.

[407] H. T. Ong, M. J. Federspiel, C. M. Guo, et al., “Systemically Delivered Measles Virus-Infected Mesenchymal Stem Cells Can Evade Host Immunity to Inhibit Liver Cancer Growth,” Journal of Hepatology 59, no. 5 (2013): 999–1006.

[408] S. Lal and C. Raffel, “Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma,” Methods in Molecular Biology 2423 (2022): 165–177.

[409] Y. Xiao, D. Ma, S. Zhao, et al., “Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer,” Clinical Cancer Research 25, no. 16 (2019): 5002–5014.

[410] J. S. Park, M. E. Lee, J. Kim, et al., “PD-1 Inhibitor Plus Oncolytic Vaccinia Virus Is a Safe and Effective Treatment Option for Metastatic Renal Cell Carcinoma,” Cancer Cell International 24, no. 1 (2024): 50.

[411] H. Zhang, Y. Ren, F. Wang, et al., “The Long-Term Effectiveness and Mechanism of Oncolytic Virotherapy Combined With Anti-PD-L1 Antibody in Colorectal Cancer Patient,” Cancer Gene Therapy 31, no. 9 (2024): 1412–1426.

[412] M. Y. Xu, N. Zeng, and C. Q. Liu, “Enhanced Cellular Therapy: Revolutionizing Adoptive Cellular Therapy,” Experimental Hematology & Oncology 13, no. 1 (2024): 47.

[413] W. Peng, J. Q. Chen, C. Liu, et al., “Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy,” Cancer Discovery 6, no. 2 (2016): 202–216.

[414] W. Dong, X. Wu, S. Ma, et al., “The Mechanism of Anti-PD-L1 Antibody Efficacy Against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector,” Cancer Discovery 9, no. 10 (2019): 1422–1437.

[415] M. Balood, M. Ahmadi, T. Eichwald, et al., “Nociceptor Neurons Affect Cancer Immunosurveillance,” Nature 611, no. 7935 (2022): 405–412.

[416] L. A. McIlvried, M. A. Atherton, N. L. Horan, et al., “Sensory Neurotransmitter Calcitonin Gene-Related Peptide Modulates Tumor Growth and Lymphocyte Infiltration in Oral Squamous Cell Carcinoma,” Advanced Biology (Weinheim) 6, no. 9 (2022): e2200019.

[417] M. A. Landy, M. Goyal, K. M. Casey, et al., “Loss of Prdm12 During Development, but Not in Mature Nociceptors, Causes Defects in Pain Sensation,” Cell Reports 34, no. 13 (2021): 108913.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.